MAXIVAX SA has a total of 16 patent applications. Its first patent ever was published in 2003. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are EUROCINE VACCINES AB, AMPLIPHI BIOSCIENCES CORP and KALINSKI PAWEL.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Australia | 1 | |
#5 | Canada | 1 | |
#6 | China | 1 | |
#7 | Hong Kong | 1 | |
#8 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Climate change adaptation technologies | |
#5 | Fermentation | |
#6 | Syringes | |
#7 | Object sterilising | |
#8 | Implantable devices |
# | Name | Total Patents |
---|---|---|
#1 | Mach Nicolas | 16 |
#2 | Lathuilière Aurélien | 4 |
#3 | Grogg Julien | 2 |
#4 | Salmon Patrick | 2 |
Publication | Filing date | Title |
---|---|---|
EP3778875A1 | Immortalized myoblast cell lines and uses thereof | |
EP3777827A1 | Implantable capsule | |
EP3352783A1 | Vaccination with immuno-isolated cells producing an immunomodulator |